ClinicalTrials.gg
Active, not recruitingNCT04562389SENTRYUpdated Nov 4, 2026

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

A Phase 3 interventional study of Selinexor and Selinexor in Myelofibrosis, sponsored by Karyopharm Therapeutics Inc. Active, not recruiting at 166 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Karyopharm Therapeutics Inc · Phase 3, Interventional, and Treatment

Updated Oct 1, 20263 sites added3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 453 studies in Primary Myelofibrosis with a site in United States — 70 open to participants now, 105 under way, 12 of them phase 3. Primary Myelofibrosis · United States.

Enrollment
15th of 387
353 · median 40
Started
2021
with 26 others
Phase 3
42 of 453
4 open now
Primary completion
2026-02
later than 20 of 104 live
Registered
365th of 453
by date

Among the 453 studies in Primary Myelofibrosis with a site in United States, this one is the 15th largest by enrollment of the 387 interventional ones that give a count, is one of 27 that started in 2021, is one of 42 in phase 3, reaches primary completion later than 20 of the 104 other live ones, and was the 365th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

70 of the 453 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 453 studies in Primary Myelofibrosis with a site in United States, or all of them as a file.
02

Study summary

This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a dose expansion part (Phase 1b). Phase 3 (ongoing), double-blind, placebo-controlled part of the study comparing the efficacy and safety of combination therapy of selinexor + ruxolitinib with combination of placebo + ruxolitinib.

03

Conditions studied

  • Myelofibrosis

Keywords

  • Myelofibrosis
  • Selinexor
  • Ruxolitinib
  • Janus kinase 2
  • Myeloproliferative neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years
  • A diagnosis of primary MF or post-essential thrombocythemia (ET) or postpolycythemia- vera (PV) MF.
  • Active symptoms of MF as determined by presence of at least 2 symptoms using the Myelofibrosis Symptom Assessment Form (MFSAF) V4.0.
  • Participants with international prognostic scoring system (DIPSS) risk category of intermediate-1, or intermediate-2, or high-risk.
  • Measurable splenomegaly during the screening period as demonstrated by spleen volume of greater than or equal to (>=) 450 cubic centimeter (cm\^3) .
  • (ECOG) Performance Status less than or equal to (\<=) 2.

Exclusion criteria

Exclusion Criteria:

  • More than 10% blasts in peripheral blood or bone marrow (accelerated or blast phase).
  • Previous treatment with JAK inhibitors for MF.
  • Previous treatment with selinexor or other XPO1 inhibitors.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    Phase 1a: Cohort 1: Selinexor 40 mg + Ruxolitinib BID

    Participants with MF will receive a dose of 40 milligrams (mg) selinexor oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with 15 or 20 mg ruxolitinib twice a day (BID) based on the participants baseline platelet count.

    Drug: Selinexor · Drug: Ruxolitinib

  • Experimental
    Phase 1a: Cohort 2: Selinexor 60 mg + Ruxolitinib BID

    Participants with MF will receive a dose of 60 mg selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle in combination with 15 or 20 mg ruxolitinib BID based on the participants baseline platelet count.

    Drug: Selinexor · Drug: Ruxolitinib

  • Experimental
    Phase 1b: Selinexor and Ruxolitinib BID

    Participants with MF will receive a dose of 40 or 60 mg selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle in combination with 15 or 20 mg ruxolitinib BID based on the participants baseline platelet count.

    Drug: Selinexor · Drug: Ruxolitinib

  • Experimental
    Phase 3: Selinexor 60 mg + Ruxolitinib BID

    Participants with MF will receive a fixed starting dose of 60 mg selinexor (RD) oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle in combination with a starting dose of 15 or 20 mg ruxolitinib BID based on the participants baseline platelet count.

    Drug: Selinexor · Drug: Ruxolitinib

  • Active comparator
    Phase 3: Placebo + Ruxolitinib BID

    Participants with MF will receive a matching placebo of selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle in combination with a starting dose of 15 or 20 mg ruxolitinib BID based on the participants baseline platelet count.

    Other: Placebo · Drug: Ruxolitinib

Interventions

  • Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.

    Also known as: KPT-330

  • Participants will receive a dose of 60 mg selinexor oral tablets QW.

    Also known as: KPT-330

  • OtherPlacebo

    Participants will receive a matching placebo of selinexor oral tablets QW

  • Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.

06

What researchers measure

Primary outcomes

  1. Phase 3: Proportion of Participants with Spleen Volume Reduction (SVR) of Greater than or Equal to (>=) 35 Percent (%) (SVR35) at Week 24 Measured by the Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan

    Time frame: At Week 24

  2. Phase 3: Absolute mean change in TSS (Abs-TSS) from baseline to Week 24 as measured by the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0

    Time frame: At Week 24

  3. Phase 1: Maximum Tolerated Dose (MTD)

    Time frame: Approximately within the first cycle (28 days) of therapy

  4. Phase 1: Recommended Phase 2 Dose (RP2D)

    Time frame: Approximately within the first cycle (28 days) of therapy

  5. Phase 1: Number of Participants With Adverse Events (AEs) by Occurrence, Nature, and Severity

    Time frame: From start of drug administration up to 30 days after last dose of study treatment (approximately 48 months)

Secondary outcomes

  1. Phase 3: Overall survival (OS)

    Time frame: From Baseline up to EoS (approximately 48 months)

  2. Phase 3: Progression-free survival (PFS)

    Time frame: Time from randomization until disease progression or death, whichever occurs first (approximately 48 months)

07

Study locations

166 sites

Showing the first 100 of 166 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Bose P, Ali H, Al-Ali HK, Garcia-Gutierrez V, Grosicki S, Grudeva-Popova Z, Harrison C, Hong J, Hou HA, Kwiatek M, Loschi M, Passamonti F, Patriarca A, Podoltsev N, Rampal R, Tantravahi S, Urian LG, Chai Y, Taverna P, Mark T, Sadiq A, Rangwala R, Vachhani P, Mascarenhas J; SENTRY Trial Investigators. Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naive Myelofibrosis: Phase III SENTRY Trial. J Clin Oncol. 2026 Aug;44(22):2098-2109. doi: 10.1200/JCO-26-01080. Epub 2026 Jun 2. PubMed 42227656 ↗
  • Ali H, Mohan S, Kishtagari A, Prchal JT, Maher K, Chai Y, Gudi G, Taverna P, Mark T, Tantravahi SK. Selinexor plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: a multicenter, open-label, phase 1 study. Blood Adv. 2026 May 26;10(10):3383-3397. doi: 10.1182/bloodadvances.2025018706. PubMed 41785311 ↗
  • Mascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, Chai Y, Kye S, Method M, Harrison C; SENTRY investigators. Selinexor plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis: SENTRY Phase 3 study design. Future Oncol. 2025 Mar;21(7):807-813. doi: 10.1080/14796694.2025.2461393. Epub 2025 Feb 6. PubMed 39911057 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Feb 2026, 59 months.

Of 22 phase 3 interventional studies under Primary Myelofibrosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 68. This study's 59 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2020
First posted
Sep 24, 2020
StartActual
Mar 11, 2021
Primary completionActual
Feb 20, 2026
CompletionEst.
Mar 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (3 Israel)
  • Shamir Medical Center · Be’er Ya‘aqov, Israel
  • Hadassah University Hospital Mount Scopus · Jerusalem, Israel
  • Galilee Medical Center · Nahariya, Israel
Show 3 removed
  • Shamir Medical Center (Assaf Harofeh) · Be’er Ya‘aqov, Israel
  • Hadassah University Hospital - Mount Scopus - Satellite Site · Jerusalem, Israel
  • Western Galilee Hospital-Nahariya · Nahariya, Israel
Oct 1, 2026
Show all 2 updates
  1. Nov 4, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Oct 1, 2026
    3 sites added, 3 sites removed
    Show 3 added (3 Israel)
    • Shamir Medical Center · Be’er Ya‘aqov, Israel
    • Hadassah University Hospital Mount Scopus · Jerusalem, Israel
    • Galilee Medical Center · Nahariya, Israel
    Show 3 removed
    • Shamir Medical Center (Assaf Harofeh) · Be’er Ya‘aqov, Israel
    • Hadassah University Hospital - Mount Scopus - Satellite Site · Jerusalem, Israel
    • Western Galilee Hospital-Nahariya · Nahariya, Israel
    + 3 other changes: identifiers, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04562389
Responsible party
Sponsor
First posted
Sep 24, 2020
Start date
Mar 11, 2021
Primary completion
Feb 20, 2026
Completion
Mar 2028 (estimated)
Last update
Nov 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion